Daphne Quimi - 09 Jun 2022 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Director
Signature
/s/ Joshua B. Cohen, as Attorney-in-Fact
Issuer symbol
AMLX
Transactions as of
09 Jun 2022
Net transactions value
$0
Form type
4
Filing time
10 Jun 2022, 16:05:16 UTC
Previous filing
19 Jan 2022
Next filing
21 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (Right to Buy) Award $0 +19,000 $0.000000 19,000 09 Jun 2022 Common Stock 19,000 $13.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director.